Current and emerging pharmacotherapy for the treatment of Lennox-Gastaut syndrome

References

• Camfield PR. Definition and natural history of Lennox-Gastaut syndrome. Epilepsia. 2011;52(s5):3–9.
   PubMedGoogle Scholar
• Asadi-Pooya AA. Lennox-Gastaut syndrome: a comprehensive review. Neurol Sci. 2018;39(3):403–414.
   PubMed Web of Science ®Google Scholar
• Specchio N, Pietrafusa N, Perucca E, et al. New paradigms for the treatment of pediatric monogenic epilepsies: progressing toward precision medicine. Epilepsy Behav. 2022;131(Pt B):107961. PubMed PMID: 2515134898; 33867301; eng. DOI:10.1016/j.yebeh.2021.107961
   PubMedGoogle Scholar
• Arzimanoglou A, French J, Blume WT, et al. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol. 2009;8(1):82–93. DOI:10.1016/S1474-4422(08)70292-8
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). NICE Guideline (NG217). Epilepsies in children, young people and adults. 2022 [cited 2023 Feb 2]. Ava: https://www.nice.org.uk/guidance/ng217/chapter/6-Treating-childhood-onset-epilepsies#lennoxgastuat-syndrome.
   Google Scholar
• Medicines and Healthcare products Regulatory Agency (MHRA). Valproate: reminder of current Pregnancy prevention programme requirements; information on new safety measures to be introduced in the coming months 2022 [ updated 12 Dec; cited 2023 Feb 2]. Available from: https://www.gov.uk/drug-safety-update/valproate-reminder-of-current-pregnancy-prevention-programme-requirements-information-on-new-safety-measures-to-be-introduced-in-the-coming-months#:~:text=In%202022%2C%20the%20Commission%20on,potential%20risks%20in%20male%20patients.
   Google Scholar
• Devinsky O, Patel AD, Cross JH, et al. Effect of cannabidiol on drop seizures in the Lennox–Gastaut syndrome. N Engl J Med. 2018;378(20):1888–1897. PubMed PMID: 29768152. DOI:10.1056/NEJMoa1714631
   PubMed Web of Science ®Google Scholar
• Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (London, England). 2018 Mar 17;391(10125):1085–1096. PubMed PMID: 29395273; eng. DOI:10.1016/s0140-6736(18)30136-3
   PubMed Web of Science ®Google Scholar
• Crumrine P, Dreifuss F, Corwin H, et al. Double-blind, placebo-controlled evaluation of cinromide in patients with the Lennox-Gastaut syndrome. Epilepsia. 1989;30(4):422–429.
   PubMed Web of Science ®Google Scholar
• Ng YT, Conry JA, Drummond R, et al. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology. 2011;77(15):1473–1481. DOI:10.1212/WNL.0b013e318232de76
   PubMed Web of Science ®Google Scholar
• Felbamate Study Group in Lennox-Gastaut Syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). N Engl J Med. 1993;328(1):29–33. PubMed PMID: 8347179. DOI:10.1056/nejm199301073280105
   PubMed Web of Science ®Google Scholar
• Knupp KG, Scheffer IE, Ceulemans B, et al. Efficacy and safety of fenfluramine for the treatment of seizures associated with Lennox-Gastaut syndrome: a randomized clinical trial. JAMA Neurol. 2022;79(6):554–564. DOI:10.1001/jamaneurol.2022.0829
   PubMed Web of Science ®Google Scholar
• Battaglia A, Ferrari AR, Guerrini R. Double-blind placebo-controlled trial of flunarizine as add-on therapy in refractory childhood epilepsy. Brain Dev. 1991 Jul;13(4):217–222. PubMed PMID: 598161309; 1957968; eng. DOI:10.1016/S0387-7604(12)80052-0
   PubMed Web of Science ®Google Scholar
• Eriksson AS, Nergårdh A, Hoppu K. The efficacy of lamotrigine in children and adolescents with refractory generalized epilepsy: a randomized, double-blind, crossover study. Epilepsia. 1998 May;39(5):495–501. PubMed PMID: 588845866; 9596201; eng. DOI:10.1111/j.1528-1157.1998.tb01411.x.
   PubMed Web of Science ®Google Scholar
• Motte J, Trevathan E, Arvidsson JF, et al. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut study group. N Engl J Med. 1997 Dec 18;337(25):1807–1812. PubMed PMID: 588205150; 9400037; eng. DOI: 10.1056/NEJM199712183372504.
   PubMed Web of Science ®Google Scholar
• Ohtsuka Y, Yoshinaga H, Shirasaka Y, et al. Rufinamide as an adjunctive therapy for Lennox–Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan. Epilepsy Res. 2014;108(9):1627–1636.
   PubMed Web of Science ®Google Scholar
• Glauser T, Kluger G, Sachdeo R, et al. Rufinamide for generalized seizures associated with Lennox–Gastaut syndrome. Neurology. 2008;70(21):1950–1958.
   PubMed Web of Science ®Google Scholar
• Hahn CD, Jiang Y, Villanueva V, et al. A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox–Gastaut syndrome (ELEKTRA). Epilepsia. 2022;63(10):2671–2683. DOI:10.1111/epi.17367
   PubMed Web of Science ®Google Scholar
• Halford JJ, Sperling MR, Arkilo D, et al. A phase 1b/2a study of soticlestat as adjunctive therapy in participants with developmental and/or epileptic encephalopathies. Epilepsy Res. 2021;174:106646.
   PubMed Web of Science ®Google Scholar
• Sachdeo RC, Glauser TA, Ritter F, et al. A double-blind, randomized trial of topiramate in Lennox–Gastaut syndrome. Neurology. 1999;52(9):1882. DOI:10.1212/wnl.52.9.1882
   PubMed Web of Science ®Google Scholar
• Patel AD, Mazurkiewicz-Bełdzińska M, Chin RF, et al. Long-term safety and efficacy of add-on cannabidiol in patients with Lennox–Gastaut syndrome: results of a long-term open-label extension trial. Epilepsia. 2021;62(9):2228–2239. DOI:10.1111/epi.17000
   PubMed Web of Science ®Google Scholar
• Thiele E, Marsh E, Mazurkiewicz-Beldzinska M, et al. Cannabidiol in patients with Lennox-Gastaut syndrome: interim analysis of an open-label extension study. Epilepsia. 2019;60(3):419–428. DOI:10.1111/epi.14670
   PubMed Web of Science ®Google Scholar
• Conry JA, Ng Y-T, Kernitsky L, et al. Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years. Epilepsia. 2014 Apr;55(4):558–567. PubMed PMID: 1503728506; 24580023; eng. DOI:10.1111/epi.12561.
   PubMed Web of Science ®Google Scholar
• Ng Y-T, Conry J, Paolicchi J, et al. Long-term safety and efficacy of clobazam for Lennox–Gastaut syndrome: interim results of an open-label extension study. Epilepsy Behav. 2012;25(4):687–694. DOI:10.1016/j.yebeh.2012.09.039
   PubMed Web of Science ®Google Scholar
• Dodson WE. Felbamate in the treatment of Lennox-Gastaut syndrome: results of a 12-month open-label study following a randomized clinical trial. Epilepsia. 1993;34(s7):S18–24.
   PubMedGoogle Scholar
• Knupp KG, Scheffer IE, Ceulemans B, et al. Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox–Gastaut syndrome: interim analysis of an open-label extension study. Epilepsia. 2022;64(1):139–151. DOI:https://doi.org/10.1111/epi.17431
   PubMed Web of Science ®Google Scholar
• Ohtsuka Y, Yoshinaga H, Shirasaka Y, et al. Long-term safety and seizure outcome in Japanese patients with Lennox–Gastaut syndrome receiving adjunctive rufinamide therapy: an open-label study following a randomized clinical trial. Epilepsy Res. 2016;121:1–7.
   PubMed Web of Science ®Google Scholar
• Kluger G, Glauser T, Krauss G, et al. Adjunctive rufinamide in Lennox-Gastaut syndrome: a long-term, open-label extension study. Acta Neurol Scand. 2010;122(3):202–208. DOI:10.1111/j.1600-0404.2010.01334.x
   PubMed Web of Science ®Google Scholar
• Glauser TA, Levisohn PM, Ritter F, et al. Topiramate in Lennox-Gastaut syndrome: open-label treatment of patients completing a randomized controlled trial. Topiramate YL study group. Epilepsia. 2000;41(S1):86–90. PubMed PMID: 593048869; 10768308; eng. DOI: 10.1111/j.1528-1157.2000.tb02179.x.
   PubMedGoogle Scholar
• Kim HJ, Kim SH, Kang H-C, et al. Adjunctive levetiracetam treatment in pediatric Lennox-Gastaut syndrome. Pediatr Neurol. 2014;51(4):527–531. DOI:10.1016/j.pediatrneurol.2014.06.004
   PubMed Web of Science ®Google Scholar
• Huber B, Bömmel W, Hauser I, et al. Efficacy and tolerability of levetiracetam in patients with therapy-resistant epilepsy and learning disabilities. Seizure. 2004 Apr;13(3):168–175. PubMed PMID: 697460173; 38404630; Eng. DOI:10.1016/S1059-1311(03)00154-7.
   PubMed Web of Science ®Google Scholar
• Rey E, Bulteau C, Motte J, et al. Oxcarbazepine pharmacokinetics and tolerability in children with inadequately controlled epilepsy. J Clin Pharmacol. 2004 Nov;44(11):1290–1300. PubMed PMID: 700784109; 39391488; Eng. doi:10.1177/0091270004266617.
   PubMed Web of Science ®Google Scholar
• Caraballo RH, Flesler S, Reyes Valenzuela G, et al. Sulthiame add-on therapy in children with Lennox-Gastaut syndrome: a study of 44 patients. Seizure. 2018;62:55–58.
   PubMed Web of Science ®Google Scholar
• Feucht M, Brantner-Inthaler S. Gamma-vinyl-GABA (vigabatrin) in the therapy of Lennox-Gastaut syndrome: an open study. Epilepsia. 1994 Sep;35(5):993–998. PubMed PMID: 581559999; 7925171; eng. DOI:10.1111/j.1528-1157.1994.tb02544.x.
   PubMed Web of Science ®Google Scholar
• Kelemen A, Rásonyl G, Neuwirth M, et al. Our clinical experience with zonisamide in resistant generalized epilepsy syndromes. Ideggyogy Sz. 2011 Mar 30;64(5–6):187–192. PubMed PMID: 873239594; 21688720; eng.
   PubMedGoogle Scholar
• You SJ, Kang H-C, Kim HD, et al. Clinical efficacy of zonisamide in Lennox–Gastaut syndrome: korean multicentric experience. Brain Dev. 2008;30(4):287–290. DOI:10.1016/j.braindev.2007.09.004
   PubMed Web of Science ®Google Scholar
• Nissenkorn A, Tzadok M, Bar-Yosef O, et al. Treatment with brivaracetam in children – the experience of a pediatric epilepsy center. Epilepsy Behav. 2019;101:106541.
   PubMed Web of Science ®Google Scholar
• Willems LM, Bertsche A, Bösebeck F, et al. Efficacy, retention, and tolerability of brivaracetam in patients with epileptic encephalopathies: a multicenter cohort study from Germany. Front Neurol. 2018 Jul;9. English. DOI:10.3389/fneur.2018.00569.
   Web of Science ®Google Scholar
• Choi HS, Kim SH, Kang H-C, et al. Efficacy and safety of lacosamide in adolescents with Lennox-Gastaut syndrome. Ann Child Neurol. 2020;28(3):93–99. DOI:10.26815/acn.2020.00080
   Google Scholar
• Miskin C, Khurana DS, Valencia I, et al. Efficacy and tolerability of lacosamide in the treatment of children with refractory generalized epilepsy. J Child Neurol. 2016;31(7):925–928. PubMed PMID: 26887412. DOI: 10.1177/0883073816630084.
   PubMed Web of Science ®Google Scholar
• Andrade-Machado R, Luque-Navarro-de Los Reyes J, Benjumea-Cuartas V, et al. Efficacy and tolerability of add-on Lacosamide treatment in adults with Lennox–Gastaut syndrome: an observational study. Seizure. 2015;33:81–87.
   PubMed Web of Science ®Google Scholar
• Grosso S, Coppola G, Cusmai R, et al. Efficacy and tolerability of add-on lacosamide in children with Lennox-Gastaut syndrome. Acta Neurol Scand. 2014;129(6):420–424. DOI:10.1111/ane.12221
   PubMed Web of Science ®Google Scholar
• Rastogi RG, Ng Y-T. Lacosamide in refractory mixed pediatric epilepsy: a prospective add-on study. J Child Neurol. 2012;27(4):492–495. PubMed PMID: 22467791. DOI:10.1177/0883073812436741.
   PubMed Web of Science ®Google Scholar
• Segal E, Moretz K, Wheless J, et al. Prove—phase IV study of perampanel in real-world clinical care of patients with epilepsy: interim analysis in pediatric patients. J Child Neurol. 2022 Mar;37(4):256–267. PubMed PMID: 2621055146; 2014685640; Eng. DOI:10.1177/08830738211047665.
   PubMed Web of Science ®Google Scholar
• Crespel A, Tang NPL, Macorig G, et al. Open-label, uncontrolled retrospective study of perampanel in adults with Lennox-Gastaut syndrome. Seizure. 2020;75:66–69.
   PubMed Web of Science ®Google Scholar
• Auvin S, Dozieres B, Ilea A, et al. Use of perampanel in children and adolescents with Lennox–Gastaut Syndrome. Epilepsy Behav. 2017;74:59–63.
   PubMed Web of Science ®Google Scholar
• Biró A, Stephani U, Tarallo T, et al. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies: first experiences. Neuropediatrics. 2015 30;46(02):110–115. En. DOI:10.1055/s-0035-1546276.
   PubMedGoogle Scholar
• Hosain SA, Green NS, Solomon GE, et al. Nitrazepam for the treatment of Lennox-Gastaut syndrome. Pediatr Neurol. 2003 Jan;28(1):16–19. PubMed PMID: 597182208; 12657414; eng. DOI:10.1016/S0887-8994(02)00461-7.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC. Nitrazepam for refractory infantile spasms and the Lennox-Gastaut syndrome. J Child Neurol. 1996 Jan;11(1):31–34. PubMed PMID: 685326871; 26051067; Eng. DOI:10.1177/088307389601100107.
   PubMed Web of Science ®Google Scholar
• Narayanan J, Frech R, Walters S, et al. Low dose verapamil as an adjunct therapy for medically refractory epilepsy – an open label pilot study. Epilepsy Res. 2016 Oct 1;126:197–200. PubMed PMID: 1812516453; 611572869; Eng. DOI:10.1016/j.eplepsyres.2016.07.004
   PubMed Web of Science ®Google Scholar
• Nicita F, Spalice A, Papetti L, et al. Efficacy of verapamil as an adjunctive treatment in children with drug-resistant epilepsy: a pilot study. Seizure. 2014 Jan;23(1):36–40. PubMed PMID: 1474794057; 52803595; Eng. DOI:10.1016/j.seizure.2013.09.009.
   PubMed Web of Science ®Google Scholar
• Yang D, Na J-H, Kim SH, et al. Efficacy and prognosis of long-term, high-dose steroid therapy for Lennox–Gastaut syndrome. Epilepsy Res. 2022;179:106847.
   Web of Science ®Google Scholar
• Chatterjee A, Mundlamuri RC, Kenchaiah R, et al. Role of pulse methylprednisolone in epileptic encephalopathy: a retrospective observational analysis. Epilepsy Res. 2021 Jul;173. PubMed PMID: 2503484623; 2011387986; Eng. DOI:10.1016/j.eplepsyres.2021.106611.
   PubMed Web of Science ®Google Scholar
• Fernando MS, Dharmaratne GK, Gamage R. Efficacy of add on corticosteroids in the management of pharmaco resistant epilepsy in Lennox Gastaut syndrome (LGS), multi center pilot study. Int J Epilepsy. 2016;3(01):A34.
   Google Scholar
• You SJ, Jung DE, Kim HD, et al. Efficacy and prognosis of a short course of prednisolone therapy for pediatric epilepsy. Eur J Paediatr Neurol. 2008 Jul;12(4):314–320. PubMed PMID: 602216466; 17951084; eng. DOI:10.1016/j.ejpn.2007.09.003.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration (FDA). Clobazam (ONFI) prescribing information [cited 2023 Apr 9]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202067s007,203993s009lbl.pdf
   Google Scholar
• Electronic Medicines Compendium (EMC). Clobazam summary of product characteristics (SmPC) [cited 2023 Apr 9]. Ava: https://www.medicines.org.uk/emc/product/7618/smpc
   Google Scholar
• Ng YT, Collins SD. Clobazam. Neurotherapeutics. 2007 Jan;4(1):138–144. PubMed PMID: 17199029; PubMed Central PMCID: PMCPMC7479695. eng. DOI:10.1016/j.nurt.2006.11.002.
   PubMed Web of Science ®Google Scholar
• Pellock JM. Felbamate. Epilepsia. 1999;40(s5):s57–62.
   PubMedGoogle Scholar
• Rho JM, Donevan SD, Rogawski MA. Mechanism of action of the anticonvulsant felbamate: opposing effects on N-methyl-D-aspartate and γ-aminobutyric acidA receptors. Ann Neurol. 1994;35(2):229–234.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration (FDA). Felbamate (FELBATOL) prescribing information [cited 2023 Apr 9]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
   Google Scholar
• Fitton A, Goa KL. Lamotrigine: an update of its pharmacology and therapeutic use in epilepsy. Drugs. 1995 Oct;50(4):691–713. PubMed PMID: 585074112; 8536554; eng. DOI:10.2165/00003495-199550040-00008.
   PubMed Web of Science ®Google Scholar
• Brodie MJ. Lamotrigine. Lancet. 1992;339(8806):1397. PubMed PMID: edsgcl.12476138. DOI:10.1016/0140-6736(92)91207-O.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration (FDA). Lamotrigine (LAMICTAL) prescribing information [cited 2023 Apr 9]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020241s064,020764s057,022251s028lbl.pdf
   Google Scholar
• Electronic Medicines Compendium (EMC). Lamotrigine (LAMICTAL) Summary of Product Characteristics (SmPC) [cited 2023 Apr 9]. Available from: https://www.medicines.org.uk/emc/product/8052/smpc
   Google Scholar
• Goldsmith DR, Wagstaff AJ, Ibbotson T, et al. Lamotrigine. Drugs. 2003;63(19):2029–2050. DOI:10.2165/00003495-200363190-00009
   PubMed Web of Science ®Google Scholar
• Kim T, Kulick CG, Kortepeter CM, et al. Hemophagocytic lymphohistiocytosis associated with the use of lamotrigine. Neurology. 2019;92(21):e2401–2405. DOI:10.1212/wnl.0000000000007517
   PubMed Web of Science ®Google Scholar
• Meador KJ, Gidal BE. Lamotrigine and hemophagocytic lymphohistiocytosis. Neurology. 2019;92(21):979–980.
   PubMed Web of Science ®Google Scholar
• Besag FMC, Berry DJ, Pool F, et al. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction? Epilepsia. 1998;39(2):183–187. DOI:10.1111/j.1528-1157.1998.tb01356.x
   PubMed Web of Science ®Google Scholar
• Arroyo S. Rufinamide. Neurotherapeutics. 2007 Jan;4(1):155–162. PubMed PMID: 704432865; 46107325; Eng. doi:10.1016/j.nurt.2006.11.006.
   PubMed Web of Science ®Google Scholar
• Wheless JW, Vazquez B. Rufinamide: a novel broad-spectrum antiepileptic drug. Epilepsy Curr. 2010;10(1):1–6. PubMed PMID: 20126329. DOI:10.1111/j.1535-7511.2009.01336.x.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration (FDA). Rufinamide (BANZEL) prescribing information [cited 2023 Apr 9]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021911s017,201367s008lbl.pdf
   Google Scholar
• Electronic Medicines Compendium (EMC). Rufinamide (INOVELON) Summary of Product Characteristics (SmPC) [cited 2023 Apr 9]. Available from: https://www.medicines.org.uk/emc/product/410/smpc
   Google Scholar
• Lyseng-Williamson KA, Yang LPH. Topiramate: a review of its use in the treatment of epilepsy. Drugs. 2007;67(15):2231–2256. PubMed PMID: 600678969; 17927286; eng. DOI:10.2165/00003495-200767150-00008.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration (FDA). Topiramate (TOPAMAX) prescribing information [cited 2023 Apr 9]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020505s064,020844s054lbl.pdf
   Google Scholar
• Electronic Medicines Compendium (EMC). Topiramate (TOPAMAX) Summary of Product Characteristics (SmPC) [cited 2023 Apr 9]. Available from: https://www.medicines.org.uk/emc/product/1977/smpc
   Google Scholar
• Mula M, Trimble MR, Thompson P, et al. Topiramate and word-finding difficulties in patients with epilepsy. Neurology. 2003;60(7):1104–1107. DOI:10.1212/01.Wnl.0000056637.37509.C6
   PubMed Web of Science ®Google Scholar
• Rosenfeld WE. Topiramate: a review of preclinical, pharmacokinetic, and clinical data. Clin Ther. 1997;19(6):1294–1308.
   PubMed Web of Science ®Google Scholar
• Lee S, Sziklas V, Andermann F, et al. The effects of adjunctive topiramate on cognitive function in patients with epilepsy. Epilepsia. 2003;44(3):339–347. DOI:10.1046/j.1528-1157.2003.27402.x
   PubMed Web of Science ®Google Scholar
• Thompson PJ, Baxendale SA, Duncan JS, et al. Effects of topiramate on cognitive function. J Neurol Neurosurg Psychiatry. 2000;69(5):636–641.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration (FDA). Cannabidiol (EPIDIOLEX) prescribing information [cited 2023 Apr 9]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210365s015lbl.pdf
   Google Scholar
• Electronic Medicines Compendium (EMC). Cannabidiol (EPIDYOLEX) Summary of Product Characteristics (SmPC) [cited 2023 Apr 9]. Available from: https://www.medicines.org.uk/emc/product/10781/smpc
   Google Scholar
• Franco V, Bialer M, Perucca E. Cannabidiol in the treatment of epilepsy: current evidence and perspectives for further research. Neuropharmacology. 2021 Mar 1;185: 108442. PubMed PMID: 2471800500; 33347884; eng. DOI:10.1016/j.neuropharm.2020.108442
   PubMed Web of Science ®Google Scholar
• Morrison G, Crockett J, Blakey G, et al. A phase 1, open-label, pharmacokinetic trial to investigate possible drug-drug interactions between clobazam, stiripentol, or valproate and cannabidiol in healthy subjects. Clin Pharmacol Drug Dev. 2019 Nov 1;8(8):1009–1031. PubMed PMID: 2312536753; 2003505884; Eng. Doi:10.1002/cpdd.665.
   PubMed Web of Science ®Google Scholar
• Gaston TE, Bebin EM, Cutter GR, et al. Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia. 2017;58(9):1586–1592. DOI:10.1111/epi.13852
   PubMed Web of Science ®Google Scholar
• Bialer M, Perucca E. Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials. Epilepsia. 2020;61(6):1082–1089.
   PubMed Web of Science ®Google Scholar
• Devinsky O, Thiele EA, Wright S, et al. Cannabidiol efficacy independent of clobazam: meta-analysis of four randomized controlled trials. Acta Neurol Scand. 2020;142(6):531–540. DOI:10.1111/ane.13305
   PubMed Web of Science ®Google Scholar
• Lattanzi S, Trinka E, Striano P, et al. Cannabidiol efficacy and clobazam status: a systematic review and meta-analysis. Epilepsia. 2020;61(6):1090–1098. DOI:10.1111/epi.16546
   PubMed Web of Science ®Google Scholar
• Gogou M, Cross JH. Fenfluramine as antiseizure medication for epilepsy. Dev Med Child Neurol. 2021;63(8):899–907.
   PubMed Web of Science ®Google Scholar
• Nordli DR, Galan FN. Fenfluramine for the treatment of dravet syndrome and lennox gastaut syndrome: a review. Curr Treat Options Neurol. 2022;24(12):631–640.
   Web of Science ®Google Scholar
• US Food and Drug Administration (FDA). Fenfluramine (FINTEPLA) prescribing information [cited 2023 Apr 9]. Ava: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212102s006lbl.pdf
   Google Scholar
• Electronic Medicines Compendium (EMC). Fenfluramine (FINTEPLA) Summary of Product Characteristics (SmPC) [cited 2023 Apr 9]. Available from: https://www.medicines.org.uk/emc/product/11998
   Google Scholar
• Halford J, Arkilo D, Asgharnejad M, et al. Initial data from the ongoing ENDYMION open-label extension trial of soticlestat (TAK-935/OV935) in participants with developmental and/or epileptic encephalopathies (DEE) (4492). Neurology. 2020;94(15 Supplement):4492.
   Web of Science ®Google Scholar
• Nishi T, Metcalf CS, Fujimoto S, et al. Anticonvulsive properties of soticlestat, a novel cholesterol 24-hydroxylase inhibitor. Epilepsia. 2022 Jun;63(6):1580–1590. PubMed PMID: 2646761974; 2015449038; Eng. DOI:10.1111/epi.17232.
   PubMed Web of Science ®Google Scholar
• Nishi T, Kondo S, Miyamoto M, et al. Soticlestat, a novel cholesterol 24-hydroxylase inhibitor shows a therapeutic potential for neural hyperexcitation in mice. Sci Rep. 2020;10(1):17081. DOI:10.1038/s41598-020-74036-6
   PubMed Web of Science ®Google Scholar
• Hawkins NA, Jurado M, Thaxton TT, et al. Soticlestat, a novel cholesterol 24-hydroxylase inhibitor, reduces seizures and premature death in Dravet syndrome mice. Epilepsia. 2021;62(11):2845–2857. DOI:10.1111/epi.17062
   PubMed Web of Science ®Google Scholar
• Pong AW, Ross J, Tyrlikova I, et al. Epilepsy: expert opinion on emerging drugs in phase 2/3 clinical trials. Expert Opin Emerg Drugs. 2022 Mar;27(1):75–90. PubMed PMID: 2644065429; 35341431; eng. DOI:10.1080/14728214.2022.2059464.
   PubMed Web of Science ®Google Scholar
• Laxer K, Blum D, Abou-Khalil BW, et al. Assessment of ganaxolone’s anticonvulsant activity using a randomized, double-blind, presurgical trial design. Ganaxolone presurgical study group. Epilepsia. 2000 Sep;41(9):1187–1194. PubMed PMID: 10999558; eng. DOI:10.1111/j.1528-1157.2000.tb00324.x.
   PubMed Web of Science ®Google Scholar
• Kerrigan JF, Shields WD, Nelson TY, et al. Ganaxolone for treating intractable infantile spasms: a multicenter, open-label, add-on trial. Epilepsy Res. 2000;42(2):133–139.
   PubMed Web of Science ®Google Scholar
• Pieribone VA, Tsai J, Soufflet C, et al. Clinical evaluation of ganaxolone in pediatric and adolescent patients with refractory epilepsy. Epilepsia. 2007;48(10):1870–1874. DOI:10.1111/j.1528-1167.2007.01182.x
   PubMed Web of Science ®Google Scholar
• Lattanzi S, Riva A, Striano P. Ganaxolone treatment for epilepsy patients: from pharmacology to place in therapy. Expert Rev Neurotherapeutics. 2021;21(11):1317–1332.
   PubMed Web of Science ®Google Scholar
• Pong AW, Xu KJ, Klein P. Recent advances in pharmacotherapy for epilepsy. Curr Opin Neurol. 2023;36(2):77–85.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration (FDA). Ganaxolone (ZTALMY) prescribing information 2022 [cited 2023 Apr 9]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215904s001s002lbl.pdf
   Google Scholar
• Devinsky O, Segal E, Chez M, et al. Open-label trial of ganaxolone in children with Lennox-Gastaut syndrome. Am Epilepsy Soc. 2020 [Cited 2023 May 23]. Avilable from: https://aesnet.org/abstractslisting/open-label-trial-of-ganaxolone-in-children-with-lennox-gastaut-syndrome?_gl=1*19vt053*_ga*NTQ4NjYwMzMyLjE2ODQ4NTM5NjU.*_ga_GV192D9FPY*MTY4NDg1Mzk2NS4xLjEuMTY4NDg1NDEyOC42MC4wLjA.
   Google Scholar
• Fromm GH, Terrence CF, Chattha AS. Effect of cinromide on inhibitory and excitatory mechanisms. Epilepsia. 1983;24(4):394–400.
   PubMed Web of Science ®Google Scholar
• Chiu P, Lipnowski S, Bruni J, et al. The effect of cinromide on “kindled” seizures in the rat. Neuropharmacology. 1982;21(3):273–276. DOI:10.1016/0028-3908(82)90198-8
   PubMed Web of Science ®Google Scholar
• Wilensky AJ, Ojemann LM, Friel PN, et al. Cinromide in epilepsy: a pilot study. Epilepsia. 1983;24(4):401–409. DOI:10.1111/j.1528-1157.1983.tb04908.x
   PubMed Web of Science ®Google Scholar
• Allen JW, Hamilton MJ, Oxley J, et al. A controlled trial of cinromide. Epilepsia. 1983;24(4):422–426. DOI:10.1111/j.1528-1157.1983.tb04910.x
   PubMed Web of Science ®Google Scholar
• Corwin HM, Dreifuss FE. Cinromide in the treatment of absence seizures. Epilepsia. 1983;24(4):427–430.
   PubMed Web of Science ®Google Scholar
• Holmes B, Brogden RN, Heel RC, et al. Flunarizine. Drugs. 1984;27(1):6–44.
   PubMedGoogle Scholar
• Hasan M, Pulman J, Marson AG .Calcium antagonists as an add‐on therapy for drug‐resistant epilepsy. Cochrane Database Syst Rev. 2013:3. PubMed PMID: CD002750. DOI:10.1002/14651858.CD002750.pub2.
   Web of Science ®Google Scholar
• Marson AG, Sills GJ. Valproate. In: Shorvon S, Perucca E, and Engel J, editors. The Treatment of Epilepsy. 4th ed. Wiley; 2015. pp. 652–666.
   Google Scholar
• Romoli M, Mazzocchetti P, D’Alonzo R, et al. Valproic acid and epilepsy: from molecular mechanisms to clinical evidences. Curr Neuropharmacol. 2019;17(10):926–946. DOI:10.2174/1570159X17666181227165722
   PubMed Web of Science ®Google Scholar
• Montouris G, Aboumatar S, Burdette D, et al. Expert opinion: proposed diagnostic and treatment algorithms for Lennox–Gastaut syndrome in adult patients. Epilepsy Behav. 2020;110:107146.
   PubMed Web of Science ®Google Scholar
• Morrow J, Russell A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK epilepsy and pregnancy register. J Neurol Neurosurg Psychiatry. 2006;77(2):193–198.
   PubMed Web of Science ®Google Scholar
• Villani F, Avanzini G. The use of immunoglobulins in the treatment of human epilepsy. Neurol Sci. 2002;23(1):S33–37.
   PubMedGoogle Scholar
• Geng J, Dong J, Li Y, et al. Intravenous immunoglobulins for epilepsy. Cochrane Database Syst Rev. 2019 12;2019(12). PubMed PMID: CD008557. DOI:10.1002/14651858.CD008557.pub4.
   Google Scholar
• Geva-Dayan K, Shorer Z, Menascu S, et al. Immunoglobulin treatment for severe childhood epilepsy. Pediatr Neurol. 2012;46(6):375–381. DOI:10.1016/j.pediatrneurol.2012.03.015
   PubMed Web of Science ®Google Scholar
• Mikati MA, Kurdi R, El-Khoury Z, et al. Intravenous immunoglobulin therapy in intractable childhood epilepsy: open-label study and review of the literature. Epilepsy Behav. 2010;17(1):90–94. DOI:10.1016/j.yebeh.2009.10.020
   PubMed Web of Science ®Google Scholar
• Illum N, Taudorf K, Heilmann C, et al. Intravenous immunoglobulin: a single-blind trial in children with Lennox-Gastaut syndrome. Neuropediatrics. 1990 May;21(2):87–90. PubMed PMID: 597073845; 2193242; eng. DOI:10.1055/s-2008-1071468.
   PubMed Web of Science ®Google Scholar
• Dubey D, Britton J, McKeon A, et al. Randomized placebo-controlled trial of intravenous immunoglobulin in autoimmune LGI1/CASPR2 epilepsy. Ann Neurol. 2020;87(2):313–323. DOI:10.1002/ana.25655
   PubMed Web of Science ®Google Scholar
• de Bruijn MAAM, van Sonderen A, van Coevorden-Hameete MH, et al. Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABABR encephalitis. Neurology. 2019;92(19):e2185–2196.
   PubMed Web of Science ®Google Scholar
• Toledano M, Britton JW, McKeon A, et al. Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy. Neurology. 2014;82(18):1578–1586. DOI:10.1212/wnl.0000000000000383
   PubMed Web of Science ®Google Scholar
• Irani SR, Bien CG, Lang B. Autoimmune epilepsies. Curr Opin Neurol. 2011 Apr;24(2):146–153. PubMed PMID: 859554307; 51301586; Eng. DOI:10.1097/WCO.0b013e3283446f05.
   PubMed Web of Science ®Google Scholar
• Wheless JW. History of the ketogenic diet. Epilepsia. 2008;49(s8):3–5.
   PubMedGoogle Scholar
• D’Andrea Meira I, Romão TT, Pires Do Prado HJ, et al. Ketogenic diet and epilepsy: what we know so far. Front Neurosci. 2019 Jan 29;13. DOI:10.3389/fnins.2019.00005.
   PubMed Web of Science ®Google Scholar
• Choudhary A, Mu C, Barrett KT, et al. The link between brain acidosis, breathing and seizures: a novel mechanism of action for the ketogenic diet in a model of infantile spasms. Brain Comm. 2021;3(4).
   PubMedGoogle Scholar
• Gasior M, Rogawski MA, Hartman AL. Neuroprotective and disease-modifying effects of the ketogenic diet. Behav Pharmacol. 2006 Sep;17(5–6):431–439. PubMed PMID: 16940764; PubMed Central PMCID: PMCPMC2367001. eng. DOI:10.1097/00008877-200609000-00009.
   PubMed Web of Science ®Google Scholar
• Sharawat IK, Panda PK, Sihag RK, et al. Efficacy and safety of corpus callosotomy and ketogenic diet in children with Lennox Gastaut syndrome: a systematic review and meta-analysis. Child’s Nerv Syst. 2021;37(8):2557–2566.
   PubMed Web of Science ®Google Scholar
• Skrobas U, Duda P, Bryliński Ł, et al. Ketogenic diets in the management of lennox-gastaut syndrome: review of literature. Nutrients. 2022;14(23):4977. PubMed PMID. DOI:10.3390/nu14234977.
   PubMed Web of Science ®Google Scholar
• Schoeler NE, Orford M, Vivekananda U, et al. K.Vita: a feasibility study of a blend of medium chain triglycerides to manage drug-resistant epilepsy. Brain Comm. 2021;3(4).
   PubMedGoogle Scholar
• Breit S, Kupferberg A, Rogler G, et al. Vagus nerve as modulator of the brain–gut axis in psychiatric and inflammatory disorders. Front Psychiatry. 2018 Mar 13;9. DOI:10.3389/fpsyt.2018.00044.
   PubMed Web of Science ®Google Scholar
• Rolston JD, Englot DJ, Wang DD, et al. Corpus callosotomy versus vagus nerve stimulation for atonic seizures and drop attacks: a systematic review. Epilepsy Behav. 2015;51:13–17.
   PubMed Web of Science ®Google Scholar
• Henry TR. Therapeutic mechanisms of vagus nerve stimulation. Neurology. 2002;59(6 suppl 4):S3–14.
   PubMed Web of Science ®Google Scholar
• Dibué M, Greco T, Spoor JKH, et al. Vagus nerve stimulation in patients with Lennox-Gastaut syndrome: a meta-analysis. Acta Neurol Scand. 2021;143(5):497–508.
   PubMed Web of Science ®Google Scholar
• Thirunavu V, Du R, Wu JY, et al. The role of surgery in the management of Lennox–Gastaut syndrome: a systematic review and meta-analysis of the clinical evidence. Epilepsia. 2021;62(4):888–907. DOI:10.1111/epi.16851
   PubMed Web of Science ®Google Scholar
• Asadi-Pooya AA, Sharan A, Nei M, et al. Corpus callosotomy. Epilepsy Behav. 2008;13(2):271–278. DOI:10.1016/j.yebeh.2008.04.020
   PubMed Web of Science ®Google Scholar
• Lancman G, Virk M, Shao H, et al. Vagus nerve stimulation vs. corpus callosotomy in the treatment of Lennox–Gastaut syndrome: a meta-analysis. Seizure. 2013;22(1):3–8. DOI:10.1016/j.seizure.2012.09.014
   PubMed Web of Science ®Google Scholar
• Douglass LM, Salpekar J. Surgical options for patients with Lennox-Gastaut syndrome. Epilepsia. 2014;55(s4):21–28.
   PubMedGoogle Scholar
• Shlobin NA, Hofmann K, Cohen NT, et al. Deep brain stimulation of the centromedian nucleus of the thalamus for Lennox-Gastaut syndrome: a systematic review and individual patient data analysis. Neurosurgery. 2023;92(4):703–715. PubMed PMID: 00006123-202304000-00007. DOI:10.1227/neu.0000000000002280.
   PubMed Web of Science ®Google Scholar
• Alanazi RF, Alkhani AM. Management of Lennox-Gastaut syndrome with deep brain stimulation: a systematic literature review. Neurosci J. 2022;27(4):216–220.
   Google Scholar
• Dalic LJ, Warren AEL, Bulluss KJ, et al. DBS of thalamic centromedian nucleus for lennox–gastaut syndrome (ESTEL Trial). Ann Neurol. 2022;91(2):253–267.
   PubMed Web of Science ®Google Scholar
• Warren AEL, Dalic LJ, Bulluss KJ, et al. The optimal target and connectivity for deep brain stimulation in Lennox–Gastaut syndrome. Ann Neurol. 2022;92(1):61–74.
   PubMed Web of Science ®Google Scholar
• Perucca E, Brodie MJ, Kwan P, et al. 30 years of second-generation antiseizure medications: impact and future perspectives. Lancet Neurol. 2020;19(6):544–556. DOI:10.1016/S1474-4422(20)30035-1
   PubMed Web of Science ®Google Scholar
• Rho JM, White HS. Brief history of anti-seizure drug development. Epilepsia Open. 2018;3(S2):114–119.
   PubMedGoogle Scholar
• Perucca E. The pharmacological treatment of epilepsy: recent advances and future perspectives. Acta Epileptologica. 2021;3(1):22.
   Google Scholar
• Perucca E. Pharmacological and therapeutic properties of valproate. CNS Drugs. 2002;16(10):695–714.
   PubMed Web of Science ®Google Scholar
• Ornoy A. Valproic acid in pregnancy: how much are we endangering the embryo and fetus? Reprod Toxicol. 2009;28(1):1–10.
   PubMed Web of Science ®Google Scholar
• Brigo F, Jones K, Eltze C, et al. Anti‐seizure medications for Lennox‐Gastaut syndrome. Cochrane Database Syst Rev. 2021;4. PubMed PMID: CD003277. DOI:10.1002/14651858.CD003277.pub4.
   PubMedGoogle Scholar
• Devi N, Madaan P, Ameen R, et al. Short-term and long-term efficacy and safety of antiseizure medications in Lennox Gastaut syndrome: a network meta-analysis. Seizure. 2022;99:164–175.
   PubMed Web of Science ®Google Scholar
• Zhang L, Wang J, Wang C. Efficacy and safety of antiseizure medication for Lennox–Gastaut syndrome: a systematic review and network meta-analysis. Dev Med Child Neurol. 2022;64(3):305–313. DOI:10.1111/dmcn.15072.
   PubMed Web of Science ®Google Scholar
• Besag FM. Subtle cognitive and behavioral effects of epilepsy. (UK): Cambridge University Press; 2002.
   Google Scholar
• Besag FMC. Behavioural effects of the new anticonvulsants. Drug Saf. 2001;24(7):513–536.
   PubMed Web of Science ®Google Scholar
• Moavero R, Santarone ME, Galasso C, et al. Cognitive and behavioral effects of new antiepileptic drugs in pediatric epilepsy. Brain Dev. 2017;39(6):464–469. DOI:10.1016/j.braindev.2017.01.006
   PubMed Web of Science ®Google Scholar
• Loring DW, Marino S, Meador KJ. Neuropsychological and behavioral effects of antiepilepsy drugs. Neuropsychol rev. 2007;17(4):413–425.
   PubMed Web of Science ®Google Scholar